Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Artiva Biotherapeutics, Inc.ARTV · Entity 5404 | Director | July 18, 2024 | July 19, 2024 |
| C4 Therapeutics, Inc.CCCC · Entity 5503 | Director | June 24, 2026 | June 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Artiva Biotherapeutics, Inc.
Report date July 18, 2024 · Filed July 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.01 · Expires 2033-04-02 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-07-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Vesting is monthly over a 36-month period starting March 3, 2022 in equal monthly amounts. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.47 · Expires 2034-05-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-07-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: 100% of the shares vest upon the earlier of (i) the first anniversary of the initial public offering of the Issuer and (ii) date of the next annual meeting of stockholders of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting is monthly over a 36-month period starting March 3, 2022 in equal monthly amounts.
F2: 100% of the shares vest upon the earlier of (i) the first anniversary of the initial public offering of the Issuer and (ii) date of the next annual meeting of stockholders of the Issuer.
C4 Therapeutics, Inc.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2036-06-23 | Direct | 62,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 62,000 · Balance 62,000 F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 26, 2026 20:28 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001470831-26-000661 · wk-form4_1782505691.xml · derivative · entry 1 Bessen Laura · CIK 0001926815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:11 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 35,500 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001662579-25-000045 · wk-form4_1750450270.xml · derivative · entry 1 Bessen Laura · CIK 0001926815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,500 Underlying: Common Stock · 35,500 shares Expires 2035-06-17 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:08 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 32,500 | $0.00 Strike: $4.05 | $0.00 |
DisclosureSEC source: 0001662579-24-000059 · wk-form4_1719000521.xml · derivative · entry 1 Bessen Laura · CIK 0001926815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2034-06-19 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 20, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:24 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001662579-23-000061 · wk-form4_1686947089.xml · derivative · entry 1 Bessen Laura · CIK 0001926815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 15, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 20:23 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 41,200 | $0.00 Strike: $9.64 | $0.00 |
DisclosureSEC source: 0001209191-22-043869 · doc4.xml · derivative · entry 1 Bessen Laura · CIK 0001926815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2032-07-28 F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on July 29, 2023, with the remainder vesting in eight equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.